Suppr超能文献

医学血管成形术——希望与期望:乐观概述

Medical angioplasty - hope and expectations: an optimistic overview.

作者信息

Abdul-Mohsen Mohammed F

机构信息

Department of Internal Medicine, King Fahd Hospital of the University and Medical College, University of Dammam, Dammam, Saudi Arabia.

出版信息

J Family Community Med. 2011 Sep;18(3):101-10. doi: 10.4103/2230-8229.90007.

Abstract

Primary and secondary prevention of cardiovascular diseases (CVD) are markedly overlooked worldwide. The use of these kinds of preventive methods will greatly improve outcome of or even reverse major CVD, especially coronary atherosclerosis. Comprehensive lifestyle changes combined with aggressive medical therapy [lipid lowering agents "statins", antiplatelet agents, beta-blockers and angiotensin-converting enzyme inhibitors] for patients suffering from coronary heart disease significantly reduce all major adverse cardiovascular events (MACE), especially in those with stable coronary artery disease (CAD), even if their coronary lesions are significant. The main mechanistic pathways for the significant reduction of MACE are: Stabilization of atheromatous plaques through endothelial function reparation, strengthening of the fibrous cap of the atheromatous plaque and reduction of atheroma burden, i.e., reversal of the process of coronary artery stenosis, the great dream of "medical angioplasty". Despite the compelling data indicating the great beneficial effects of both primary and secondary prevention of coronary atherosclerosis, the US national survey data reveals that only a minority of patients eligible by guidelines for these therapies in fact receive them. Hence, we strongly believe that our main duties as cardiologists is to improve the up-to-date knowledge of the practicing physicians about utility of aggressive medical therapy for both prevention and reversal of CVD, and also to promote useful primary and secondary prevention programs among physicians and patients. Meanwhile, further improvement and refinement of the current therapeutic modalities and introduction of new modalities for the management of lipid parameters other than LDL-C, such as HDL-C, triglyceride, lipoprotein (a), LDL particle size and susceptibility to oxidation may add further favourable effects in prevention and reversal of atherosclerotic process. Cardiologists should be just as aggressive with prevention as many have been with intervention. This optimistic overview is a valley cry to all practicing physicians; please depart from usual methods of intervention to preventive strategies which are largely overlooked.

摘要

心血管疾病(CVD)的一级和二级预防在全球范围内都被严重忽视。采用这类预防方法将极大地改善主要心血管疾病的预后,甚至使其逆转,尤其是冠状动脉粥样硬化。对于冠心病患者,综合生活方式的改变与积极的药物治疗[降脂药物“他汀类药物”、抗血小板药物、β受体阻滞剂和血管紧张素转换酶抑制剂]相结合,可显著减少所有主要不良心血管事件(MACE),尤其是在那些患有稳定冠状动脉疾病(CAD)的患者中,即使他们的冠状动脉病变严重。MACE显著减少的主要机制途径是:通过修复内皮功能稳定动脉粥样硬化斑块,加强动脉粥样硬化斑块的纤维帽并减轻动脉粥样硬化负担,即逆转冠状动脉狭窄的过程,这是“药物血管成形术”的伟大梦想。尽管有令人信服的数据表明冠状动脉粥样硬化一级和二级预防都有巨大益处,但美国全国调查数据显示,实际上只有少数符合这些疗法指南标准的患者接受了治疗。因此,我们坚信,作为心脏病专家,我们的主要职责是提高执业医师对积极药物治疗在预防和逆转心血管疾病方面效用的最新认识,并在医生和患者中推广有效的一级和二级预防项目。与此同时,进一步改进和完善当前的治疗方式,并引入除低密度脂蛋白胆固醇(LDL-C)之外用于管理脂质参数的新方式,如高密度脂蛋白胆固醇(HDL-C)、甘油三酯、脂蛋白(a)、LDL颗粒大小和氧化易感性,可能会在预防和逆转动脉粥样硬化过程中增加更多有利影响。心脏病专家在预防方面应像许多人在干预方面一样积极。这一乐观的概述是对所有执业医师的强烈呼吁;请摒弃常规的干预方法,转向在很大程度上被忽视的预防策略。

相似文献

1
Medical angioplasty - hope and expectations: an optimistic overview.
J Family Community Med. 2011 Sep;18(3):101-10. doi: 10.4103/2230-8229.90007.
2
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.
3
HDL-C: role as a risk modifier.
Atheroscler Suppl. 2011 Nov;12(3):267-70. doi: 10.1016/S1567-5688(11)70885-6.
5
Optimal medical management of peripheral arterial disease.
Vasc Endovascular Surg. 2006 Aug-Sep;40(4):312-27. doi: 10.1177/1538574406291835.
7
2017 Taiwan lipid guidelines for high risk patients.
J Formos Med Assoc. 2017 Apr;116(4):217-248. doi: 10.1016/j.jfma.2016.11.013. Epub 2017 Feb 24.
8
HbA1c, Coronary atheroma progression and cardiovascular outcomes.
Am J Prev Cardiol. 2022 Jan 18;9:100317. doi: 10.1016/j.ajpc.2022.100317. eCollection 2022 Mar.
9
High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
Int J Cardiol. 2013 Oct 15;168(6):5126-34. doi: 10.1016/j.ijcard.2013.07.113. Epub 2013 Aug 24.
10
Low-density lipoprotein apheresis: an evidence-based analysis.
Ont Health Technol Assess Ser. 2007;7(5):1-101. Epub 2006 Nov 1.

本文引用的文献

1
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N Engl J Med. 2010 Dec 16;363(25):2406-15. doi: 10.1056/NEJMoa1009744. Epub 2010 Nov 17.
5
Fluvastatin and perioperative events in patients undergoing vascular surgery.
N Engl J Med. 2009 Sep 3;361(10):980-9. doi: 10.1056/NEJMoa0808207.
7
A randomized trial of therapies for type 2 diabetes and coronary artery disease.
N Engl J Med. 2009 Jun 11;360(24):2503-15. doi: 10.1056/NEJMoa0805796. Epub 2009 Jun 7.
8
A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease.
Arch Intern Med. 2009 Apr 13;169(7):659-69. doi: 10.1001/archinternmed.2009.38.
10
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.
N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验